Can a drug duo outsmart resistant T-Cell lymphoma?

NCT ID NCT03409432

Completed Disease control Sponsor: John Reneau Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining brentuximab vedotin, a targeted antibody-drug conjugate, with lenalidomide, a chemotherapy drug, can shrink tumors in people with T-cell lymphoma that has relapsed or not responded to earlier treatment. The study enrolls adults with stage IB-IVB cutaneous or peripheral T-cell lymphoma who have already tried at least one systemic therapy. Researchers will measure how many patients achieve a complete or partial response, and will also track side effects and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brentuximab vedotin (an antibody-drug conjugate) combined with lenalidomide (a chemotherapy drug)
What this could lead to: If successful, this combination could offer a new treatment option for patients with T-cell lymphoma that has returned or stopped responding to prior therapies.
What could go wrong: This is an early-phase, small trial, so results may not be definitive. The combination may cause significant side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMATOID PAPULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphomatoid papulosis mature T-cell and NK-cell non-Hodgkin lymphoma primary cutaneous anaplastic large cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMATOID PAPULOSIS PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA RECURRENT T-CELL NON-HODGKIN LYMPHOMA REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.